Study summary

Zanubrutinib plus rituximab beat chemo-immunotherapy as first treatment

MANGROVE trial · 510 people, phase 3 · Topline results June 2026 (BeOne); filings planned second half of 2026

What was tested

Zanubrutinib, a BTK inhibitor pill, plus rituximab, against bendamustine-rituximab, for untreated mantle cell lymphoma in people not suited to transplant.

What they found

Progression-free survival was significantly longer with zanubrutinib-rituximab.
Full data are expected at a future medical meeting.

What it means

A second chemotherapy-free first treatment, after ENRICH, now heading to regulators.

CancerNetwork ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.